Our keratoconus research

Clinical research

We focus on better investigating the frequency of keratoconus worldwide. Keratoconus has been referred to as a “rare disease” for more than 30 years because it appears to occur only in a human of 2,000. In a first large-scale pilot study in the Arabic-speaking world, we have now shown that in some areas of the world the disease is up to 100 times more common than previously thought. More information can be found here.

Basic research

As a co-developer of the cross-linking of the cornea, we align our entire basic research to answer open questions from the clinic around the topic of cross-linking. For example, we were the first to cross-link ectasia after LASIK and PRK in 2007 , as well as the first to treat very thin corneas with hypo-osmolar solution in 2009. We are currently focusing on developing treatment techniques that will enable the treatment of extremely thin corneas (down to 220 μm corneal thickness).

All topics are dealt with by our teams in our two research laboratories at the Universities of Zurich and USC Los Angeles.

Global leaders in keratoconus research

Brazil’s top Ophthalmology magazine, Oftalmologica Em Foco, features ELZA’s Prof. Hafezi and Dr. Torres-Netto exploring the story of how CXL at the slit lamp is becoming a reality.
We are currently developing the technique of slit lamp cross-linking, one crucial step will be to determine whether riboflavin, once applied onto the cornea, remains at saturation levels during a CXL procedure